E. Jordie

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment

D. Greenblatt, Ahmed Elmokadem, C. Housand, 2021, Journal of clinical pharmacology.

Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy

Timothy D. Knab, L. Gibiansky, J. Hernández-Sánchez, 2021, British journal of clinical pharmacology.

Bayesian PBPK modeling using R/Stan/Torsten and Julia/SciML/Turing.Jl

Timothy D. Knab, Ahmed Elmokadem, W. Gillespie, 2023, CPT: Pharmacometrics & Systems Pharmacology.

Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data

Timothy D. Knab, J. Barrett, J. Davis, 2022, Frontiers in Pharmacology.

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial

Timothy D. Knab, J. Chien, M. Riggs, 2021, Clinical pharmacology and therapeutics.

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Serafino Pantano, K. Havenith, J. Boni, 2022, Blood.

Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations

D. Greenblatt, L. Lesko, Ahmed Elmokadem, 2021, Journal of clinical pharmacology.